Related Experiment Video

Updated: May 25, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis

Xi-feng Li1, Ren-yan Gong, Meng Wang

  • 1Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.

Biochemical and Biophysical Research Communications
|January 31, 2012
PubMed

Insights

Sorafenib, a treatment for hepatocellular carcinoma (HCC), reduces the anti-apoptotic protein c-IAP1 by inhibiting its translation. Restoring c-IAP1 levels can counteract sorafenib-induced cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hepatocellular Carcinoma Research

Background:

  • Hepatocellular carcinoma (HCC) is a major cause of cancer mortality.
  • Sorafenib is a key therapeutic agent for HCC, known to induce cancer cell apoptosis.
  • The precise mechanism by which sorafenib induces apoptosis in HCC remains incompletely understood.

Purpose of the Study:

  • To elucidate the molecular mechanism underlying sorafenib-induced apoptosis in HCC.
  • To investigate the role of the anti-apoptotic protein c-IAP1 in sorafenib's efficacy.
  • To identify novel therapeutic targets or strategies for HCC treatment.

Main Methods:

  • Investigated the effect of sorafenib on c-IAP1 protein expression in HCC cells in vitro and in vivo.
  • Analyzed c-IAP1 mRNA transcription and protein stability following sorafenib treatment.
  • Examined the impact of sorafenib on c-IAP1 translation, focusing on the internal ribosome entry site (IRES).
  • Assessed the effect of ectopic c-IAP1 expression on sorafenib-induced apoptosis.

Main Results:

  • Sorafenib significantly down-regulates c-IAP1 protein expression in a time- and dose-dependent manner.
  • This down-regulation occurs at the translational level, specifically via the IRES of c-IAP1 mRNA, without affecting transcription or protein stability.
  • Overexpression of c-IAP1 partially rescues HCC cells from sorafenib-induced apoptosis.

Conclusions:

  • Sorafenib exerts its pro-apoptotic effects in HCC by inhibiting c-IAP1 translation.
  • This study reveals a novel mechanism involving IRES-mediated translation regulation in sorafenib action.
  • Findings provide mechanistic insights for optimizing sorafenib therapy in HCC patients.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...